Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.Peer-Reviewed Original ResearchEfficacious dose rangePharmacokinetics of SingleDose rangePhase 1TolerabilityPharmacokineticsRimegepant